Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
Submitted by
CP Staff
on June 27, 2018 - 9:57am
Source:
CP Wire
News Tags:
Pfizer
glasdegib
acute myeloid leukemia
Headline:
FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
snippet:
Glasdegib combined with chemotherapy almost doubled overall survival compared to chemotherapy alone
PDUFA goal date is set in December of 2018
Ph III trials began enrolling patients earlier this year
Do Not Allow Advertisers to Use My Personal information
